Evidence map›Paper›PMID 39811899›Full record

ArticleHistopathology2025

Prognostic values of molecular subtypes and SWI/SNF protein expression in de-differentiated/undifferentiated endometrial carcinoma.

Chae Young Shin, Bengul Gokbayrak, Valerie L Tao, Noorah Almadani, Eunice S Li, Rebecca Ho, Felix Kf Kommoss, Jutta Huvila, Derek Chiu, Samuel Leung and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Chae Young ShinDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Bengul GokbayrakDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0003-0504-6078
Valerie L TaoDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Noorah AlmadaniDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Eunice S LiDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Rebecca HoDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Felix Kf KommossDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0003-0876-9087
Jutta HuvilaDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0002-2685-0877
Derek ChiuOvarian Cancer Research Centre, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0002-7591-4881
Samuel LeungDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0003-0138-7254
Basile Tessier-CloutierDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0001-8739-3879
David G HuntsmanDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0001-6991-9304
C Blake GilksDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0001-7889-8250
Jessica N McAlpineOvarian Cancer Research Centre, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0001-6003-485X
Lynn HoangDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0003-3692-8057
Yemin WangDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0002-2970-9510

Funding

CIHRFaculty of Medicine, University of British ColumbiaTerry Fox Research Institute
6 · The paper itself

Abstract

aimsClassification and risk stratification of endometrial carcinoma (EC) has transitioned from histopathological features to molecular classification, e.g. the ProMisE classifier, identifying four prognostic subtypes: POLE mutant (POLEmut) with almost no recurrence or disease-specific death events, mismatch repair deficient (MMRd) and no specific molecular profile (NSMP), with intermediate outcome and p53 abnormal (p53abn) with poor outcomes. However, the applicability of molecular classification is unclear in rare but aggressive histotypes of EC, e.g. de-differentiated and undifferentiated endometrial cancers (DD/UDEC). Here, we aim to assembled a cohort of DD/UDEC from a single institution and analysed the prognostic significance of ProMisE molecular subtypes and the expression of SWItch/sucrose non-fermentable (SWI/SNF) chromatin remodelling complex members, previously implicated in the pathogenesis of DD/UDEC. METHODS AND

resultsWe accrued 88 DD/UDEC cases, assessed POLE status by Sanger sequencing and performed immunohistochemistry for p53, mismatch repair and SWI/SNF proteins on the tissue microarrays assembled. Assignment of molecular subtypes was possible in 80 tumours; POLE sequencing failed in the remaining eight cases. There were 12 (15%) POLEmut, 44 (55%) MMRd, 14 (17.5%) p53abn and 10 (12.5%) NSMP DD/UDEC. POLEmut DD/UDECs had excellent outcomes, but the other three molecular subtypes all had poor outcomes, with no significant differences among them. The loss of one or more SWI/SNF proteins [AT-rich interactive domain-containing protein 1A (ARID1A), ARID1B, SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4 (SMARCA4), SMARCA2], observed in 66% (55 of 83) cases, was not of prognostic significance.

conclusionsThese results indicate that all molecular subtypes of DD/UDEC except POLEmut behave in an aggressive fashion. Further study is needed to determine whether these molecular alterations can be targeted with adjuvant therapy, in order to improve outcomes of patients with DD/UDEC.

Indexed as

Biomarkers, TumorChromosomal Proteins, Non-HistoneEndometrial NeoplasmsTranscription FactorsAdultAgedAged, 80 and overDNA-Binding ProteinsDNA Mismatch RepairDNA Polymerase IIFemaleHumansImmunohistochemistryMiddle AgedPoly-ADP-Ribose Binding ProteinsPrognosisBiomarkers, TumorChromosomal Proteins, Non-HistoneDNA-Binding ProteinsDNA Polymerase IIPOLE protein, humanPoly-ADP-Ribose Binding ProteinsTranscription FactorsTumor Suppressor Protein p53de‐differentiated endometrial carcinomamismatch repairmolecular subtypep53POLESWI/SNFundifferentiated endometrial carcinoma

Identifiers

PMID39811899
PMCPMC12045760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.